The cell and gene therapy CDMO market is poised for remarkable growth, projected at a CAGR of approximately 24%, reaching an estimated size of USD 57.1 billion by 2034. This surge is fueled by increasing investments in regenerative medicine, CAR-T therapies, and gene editing technologies, along with a growing number of therapy candidates in clinical development. Pharmaceutical companies are increasingly partnering with CDMOs to leverage advanced manufacturing capabilities and reduce costs, driven by the complexity and stringent quality requirements of cell and gene therapies. Key players in this market include Catalent, Lonza, and Thermo Fisher Scientific, among others, and the market is currently dominated by North America, which holds about 40% of the share.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/healthcare/articles/global-cell-gene-therapy-cdmo-170000410.html
